Institute of Science Tokyo · Graduate School of Medical and Dental Sciences · 助教

Research keywordsacute myeloid leukemia・CAR-T cell therapy・hematopoietic stem cell transplantation・ferroptosis・FLT3-ITD・graft-versus-host disease・multiple myeloma・hematologic malignancies

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Yuki Nagahama, Asuka Kono, Yasumasa Nakata, Kota Yoshifuji, Keisuke Tanaka, Yoshihiro Umezawa, Takehiko Mori, Masahide Yamamoto. [Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis]. Rinsho Ketsueki. 2026; 67 (1): 50-54. ( PubMed , DOI )2026
• Keisuke Tanaka, Hiroaki Kikuchi, Yoshihiro Umezawa, Takehiko Mori, Kiyohide Fushimi, Masahide Yamamoto. Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database. Int J Hematol. 2025.08; ( PubMed , DOI )2025
• Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology. 2024.08; 120 (2): 203-211. ( PubMed , DOI )2024
• Satoshi Kaito, Yuho Najima, Daichi Sadato, Chizuko Hirama, Yuya Kishida, Akihito Nagata, Tatsuya Konishi, Yuta Yamada, Shuhei Kurosawa, Kota Yoshifuji, Shuichi Shirane, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Kyoko Haraguchi, Takeshi Kobayashi, Hironori Harada, Yoshiki Okuyama, Yuka Harada, Noriko Doki. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies. Bone Marrow Transplant. 2024.08; 59 (8): 1169-1175. ( PubMed , DOI )2024

• 日本学術振興会平成31年度科学研究費助成事業（学術研究助成金）(継続）
• PECAM－1と骨髄間質細胞が白血病難治化に及ぼす影響の検討
• 日本学術振興会令和2年度研究助成事業(学術研究助成金)
• 日本学術振興会令和２年度研究助成事業（学術研究助成金）

• Official profile